Search PubMed⌕ Search

Biomedical subjects

Johnny Ø Keller

Publications and source records attributed to Johnny Ø Keller.

3 recordsLinked to original sources

[Surgical treatment of skeletal metastases in the pelvis and extremities].

INTRODUCTION: In choosing a surgical treatment for skeletal metastases, an assessment of the individual patient's prognosis fis essential. The aim of surgical treatment is to alleviate pain and maintain function, thus improving the patient's quality of life. We analysed the survival of patients with skeletal metastases who had been surgically treated at the University Hospital in Aarhus from September 1999 to March 2003. MATERIALS AND METHODS: A consecutive series of 87 of 90 operations for non-spinal skeletal metastases was done. Three percent of the patients were operated on for more than one metastasis. Carcinomas of the breast, prostate, kidney and lung were the dominating primary tumors. RESULTS: The survival rate was 0.35 at 1 year, 0.22 at 2 years and 0.14 at 3 years. Univariate analysis showed that survival was related to sex, bone localization, skeletal metastatic load, the presence of visceral metastases, Karnofsky performance score, primary tumor type, presence of a complete pathological fracture and preoperative haemoglobin content. Multivariate regression analysis showed that pathological fracture, haemoglobin content < 7 mmol/l and a poor Karnofsky score were negative prognostic factors for survival. Breast cancer was the sole independent positive prognostic factor for survival. DISCUSSION: Most patients with two or three independent negative prognostic factors have an extremely short survival time, whereas patients with no negative prognostic factors may have a good prognosis. Surgical and reconstruction procedures should be chosen to minimise the risk of long-term failure in patients with a good prognosis and be as simple as possible in patients with a poor prognosis.

Adult↗

[Surgical treatment of giant cell tumor of bone].

INTRODUCTION: This study analyses a 5-year follow-up after treatment of giant cell tumour of bone during a 31-year period. MATERIAL AND METHODS: Sixty patients with giant cell tumours of bone had been treated at the Centre for Musculoskeletal Tumours at Aarhus University Hospital. All patients were followed at regular intervals for 5-35 years, median = 11 years. RESULTS: There were 54 benign giant cell tumours of bone, whereas six were classified as malignant. The most common location was around the knee. There were nine cases of recurrence. The 5-year recurrence-free survival was 77%. The lowest frequency of recurrence appeared after resection (6%) and the highest after bone-transplantation (22%). DISCUSSION: The classical microscopic and macroscopic criteria for malignancy are not applicable for this rare tumour. All giant cell tumours of bone should be considered as potentially malignant, and therefore patients should be referred to a Centre for Musculoskeletal Tumours.

Adolescent↗

[Sarcomas].

Explore the source record for details and available documents.

Combined Modality Therapy↗